Juan Carlos Alzate-Ángel

Juan Carlos Alzate-Ángel

Auto-generated profile, based on publicly available information

Juan Carlos Alzate-Ángel

Universidad de Antioquía

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2021 in Biomédica
Verified
Journal Article
Open access
PDF file
JBJorge Botero-Garcés
Jorge Botero-Garcés
EAEsteban Villegas Arbeláez
Esteban Villegas Arbeláez
SGSofía Giraldo
Sofía Giraldo
JUJohanna Urán-Velásquez
Johanna Urán-Velásquez
LALaura Arias-Agudelo
Laura Arias-Agudelo
AGAna Luz Galván-Díaz
Ana Luz Galván-Díaz
Introduction: HIV infection is still a public health problem worldwide and co-infections with other infectious agents including intestinal parasites are of particular concern, mainly in developing countries like Colombia.Objective: To conduct a cross-sectional study in patients attending an HIV care program in Antioquia given that there have been few intestinal parasites prevalence studies among the HIV population in the country.Material and methods: We evaluated stool samples from 192 patients by direct wet mount and concentration, modified Ziehl Neelsen staining, and agar plate culture. Univariate and correlation analyses were done to explore the association between socio-demographic and clinical characteristics and parasitological data.Results: The overall prevalence of intestinal parasites in HIV-positive subjects was 29.2% (56/192; 95% CI: 22.8% - 35.6%). Entamoeba histolytica/dispar/moshkosvkii with 13.0% (25/192; 95% CI: 8.2% - 17.8%) and Blastocystis with 12.0% (23/192; 95% CI: 7.4% - 16.6%) were the most frequent. Opportunistic parasites like Cryptosporidium spp. and Cystoisospora belli were less prevalent, each one with 0.5% of positive samples (1/192; 95% CI: 0.1% - 1.5%). Commensal protozoa were also detected with a prevalence of 18.8% (36/192; 95% CI: 13.3% - 24.3%). Most of the individuals in the study had a controlled viral load and an LTCD4 count greater than 200 cel/μL. A small percentage (9.3%) had diarrhea. Bivariate analysis and multivariate logistic regression showed that only age and having pets had a significant association with intestinal parasites in this cohort.Conclusions: Our results confirmed that the evaluated population is at high risk of intestinal parasite infection, which highlights the need for routine screening of gastrointestinal parasites to provide prompt treatment and reduce possible complications.

7 May 2020 in Colombia Medica
Verified
Journal Article
Open access
PDF file
JAJuan Carlos Alzate Angel
Juan Carlos Alzate Angel
EBERNESTO MARTÍNEZ BUITRAGO
ERNESTO MARTÍNEZ BUITRAGO
MPMaría Paulina Posada-Vergara
María Paulina Posada-Vergara
Throughout the COVID-19 pandemic, the main risk factors associated with the progression to severe disease or death have been typically advanced age, diabetes mellitus, obesity, high blood pressure, heart disease, and chronic pneumopathy. Because of their immunosuppression status, persons with HIV were also expected to have a higher susceptibility to infection or a poor clinical evolution. So far, this has not been confirmed to happen, giving way to hypotheses about the role of immunosuppression or the use of antiretrovirals, which could explain this paradox. In this article we present the existing data on the epidemiology and characteristics of HIV-COVID-19 co-infection, discuss the available evidence on the possible factors involved in the evolution of individuals affected by both viruses, analyze other determinants that may negatively affect persons with HIV during the pandemic, and present recommendations for the prevention and care of COVID-19 infection in the context of HIV.

10 April 2024 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
JAJuan C. Alzate-Ángel
Juan C. Alzate-Ángel
PAPaula A. Avilés-Vergara
Paula A. Avilés-Vergara
DADavid Arango-Londoño
David Arango-Londoño
ACAlberto Concha-Eastman
Alberto Concha-Eastman
AGAnthony Garcés-Hurtado
Anthony Garcés-Hurtado
MAMaría P. Arbeláez-Montoya
María P. Arbeláez-Montoya
Introduction: The control of the COVID-19 epidemic has been focused on the development of vaccines against SARS-CoV-2. All developed vaccines have reported safety and efficacy results in preventing infection and its consequences, although the quality of evidence varies depending on the vaccine considered. Different methodological designs have been used for their evaluation, which can influence our understanding of the effects of these interventions. CoronaVac is an inactivated vaccine, and it has been assessed in various studies, including clinical trials and observational studies. Given these differences, our objective was to explore the published information to answer the question: how has the efficacy/effectiveness and safety of CoronaVac been evaluated in different studies? This is to identify potential gaps and challenges to be addressed in understanding its effect.Methods: A scoping review was carried out following the methodology proposed by the Joanna Briggs Institute, which included studies carried out in humans as of 2020, corresponding to systematic reviews, clinical trials, analytical or descriptive observational studies, in which the effectiveness and/or safety of vaccines for COVID19 were evaluated or described. There were no age restrictions for the study participants.Results: The efficacy/effectiveness and safety of this vaccine was assessed through 113 studies. Nineteen corresponded to experimental studies, 7 of Phase II, 5 of Phase IV, and 4 were clinical trials with random assignment. Although some clinical trials with random assignment have been carried out, these have limitations in terms of feasibility, follow-up times, and with this, the possibility of evaluating safety outcomes that occur with low frequencies. Not all studies have used homogeneous methods of analysis. Both the prevention of infection, and the prevention of outcomes such as hospitalization or death, have been valued through similar outcomes, but some through multivariate analysis of dependencies, and others through analysis that try to infer causally through different control methods of confounding.Conclusion: Published information on the evaluation of the efficacy/effectiveness and safety of the CoronaVac is abundant. However, there are differences in terms of vaccine application schedules, population definition, outcomes evaluated, follow-up times, and safety assessment, as well as non-standardization in the reporting of results, which may hinder the generalizability of the findings. It is important to generate meetings and consensus strategies for the methods and reporting of this type of studies, which will allow to reduce the heterogeneity in their presentation and a better understanding of the effect of these vaccines.

1 October 2018 in American Journal of Public Health
Verified
Journal Article
Closed access
JAJuan C. Alzate Angel
Juan C. Alzate Angel
Juan M. PericàsJuan M. Pericàs
Juan M. Pericàs
HTHolly A. Taylor
Holly A. Taylor
JBJoan Benach
Joan Benach
American Journal of Public Health (AJPH) from the American Public Health Association (APHA) The American Journal of Public Health (AJPH) from the American Public Health Association (APHA)

1 January 2025 in International Journal of Microbiology
Verified
Journal Article
Open access
JAJuan C. Alzate-Angel
Juan C. Alzate-Angel
JLJohn Darío Loaiza
John Darío Loaiza
FCFederico Perdomo Celis
Federico Perdomo Celis
JHJuan C. Hernandez
Juan C. Hernandez
XGXimena Galindo-Orrego
Ximena Galindo-Orrego
NTNatalia A. Taborda
Natalia A. Taborda
Objective: The objective is to compare the clinical, virological, and immunological characteristics of people living with HIV‐1 who were treated with first‐line integrase inhibitors (INSTIs) versus those treated with other antiretrovirals. Methods: This is a descriptive observational, retrospective, two‐center study. We selected individuals who began antiretroviral therapy (ART) within the first year of diagnosis and who had received at least 1 year of treatment. Their therapy consisted of two nucleoside/nucleotide reverse transcriptase inhibitors, along with a third medication (INSTI, nonnucleoside reverse transcriptase inhibitor (NNRTI), or protease inhibitor). The primary comparison was between individuals who initiated ART containing INSTIs and those who initiated ART containing NNRTIs or protease inhibitors. We evaluated clinical outcomes, residual viral load, circulating proviral DNA, inflammation, and cardiovascular risk markers, T cell count and phenotype, and the frequency of HIV‐specific T cells. Results: Individuals who received INSTI‐based regimens started treatment at a more advanced disease stage and had a significantly shorter ART duration at study inclusion than individuals who did not receive INSTI‐based ART. Individuals receiving INSTIs achieved CD4 + T cell counts at levels comparable to those within the non‐INSTI group, as well as similar levels of virological, immunological, and cardiovascular markers. Nonetheless, those in the INSTI‐based group had higher CD8 + T cell counts and lower CD4/CD8 ratios, as well as lower high‐density lipoprotein levels. Conclusions: INSTI‐based regimens offer benefits to Colombian people living with HIV‐1, who are starting ART, including improved and faster virological and CD4 + T cell reconstitution. This occurs despite treatment initiation for advanced disease.

22 April 2025 in The Lancet Regional Health - Americas
Verified
Journal Article
Open access
IRIader Rodríguez-Márquez
Iader Rodríguez-Márquez
DBDione Benjumea-Bedoya
Dione Benjumea-Bedoya
ARAndrea Vioctroia Restrepo
Andrea Vioctroia Restrepo
CBClaudia Patricia Beltrán-Arroyave
Claudia Patricia Beltrán-Arroyave
DPDiana Marcela Marin Pineda
Diana Marcela Marin Pineda
JRJaime Robledo
Jaime Robledo
Low adherence to treatment for tuberculosis infection (TBI) in children threatens tuberculosis (TB) control goals. This research focuses on children with close contact to TB and TBI. This study evaluated adherence to treatment of TBI using a comprehensive care strategy (CCS) for close-contact children with pulmonary TB compared with standard of care (SOC). A prospective cohort study with a historical control group was conducted on children under five, who were close contacts of patients with bacteriologically confirmed pulmonary TB in three Colombian cities (study registration number: NCT04331262). The CCS comprised clinical evaluations, rifampicin for four months, multidisciplinary care, and logistical support, while the SOC followed program regulations with isoniazid for nine months. The primary outcome was the proportion of children completing 100% treatment during follow-up, and the secondary outcome was treatment-related adverse events (AEs). 213 children in the SOC group and 86 children in the CCS group were analyzed. The treatment adherence in the SOC group was 40·8% (95% CI 34%; 48%), while in the CCS group it was 76·7% (95% CI 66%; 85%). Children exposed to CCS had 87% higher probability of adherence to TBI treatment compared to SOC (RR 1·87; 95% CI 1·52; 2·31). The incidence of AEs was lower in the CCS group (n = 3) than in those receiving SOC (n = 24). The CCS increases adherence to treatment for TBI in children safely compared to SOC. Future cost-effectiveness studies will help implement this strategy in programmatic settings. Colombian Ministry of Science, Technology and Innovation.